Abstract
Reduced intensity conditioning regimens prior to allogeneic haematopoietic stem cell transplantation (HSCT) were first described in the 1970s, and have developed rapidly over the past few years to become an important consideration as immunological therapy for patients with haematological and selected solid organ malignancies. This is especially the case for patients considered ineligible for conventional allogeneic HSCT due to age or medical contraindications. With the development of minimally toxic conditioning regimens, additional potential applications include the provision of normal haematopoietic repopulating cells to patients who have an inherited gene defect such as an haemoglobinopathy or an inborn error of metabolism. Intensive investigation in stem cell research promises to provide dramatic new insights into human biology, paving the way for new therapeutic approaches to malignant and inherited disorders.
Original language | English (US) |
---|---|
Pages (from-to) | 703-714 |
Number of pages | 12 |
Journal | Expert Opinion on Biological Therapy |
Volume | 2 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2002 |
Keywords
- Graft-versus-malignancy
- Haematopoietic stem cell transplant
- Non-myeloablative
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry